Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Brain-imaging surrogate markers for detection and prevention of age-related memory loss.

Small GW.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):17-21. Review.

PMID:
12212776
2.

Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer's disease.

Small GW.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1561-6. Review.

PMID:
12453673
3.

Imaging, subjective complaints, and MCI: 30 years before.

Galluzzi S, Frisoni GB.

J Nutr Health Aging. 2008 Jan;12(1):80S-3S. Review.

PMID:
18165851
4.

Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.

VanItallie TB.

Metabolism. 2015 Mar;64(3 Suppl 1):S51-7. doi: 10.1016/j.metabol.2014.10.033. Epub 2014 Oct 30. Review.

PMID:
25468143
5.

Diminished neuronal metabolic activity in Alzheimer's disease. Review article.

Salehi A, Swaab DF.

J Neural Transm (Vienna). 1999;106(9-10):955-86. Review.

PMID:
10599878
6.

[The role of cholesterol in Alzheimer's neuro-pathogenesis].

Biondi E.

Riv Biol. 2006 May-Aug;99(2):210-5. Review. Italian.

PMID:
17115369
7.

Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.

Small GW.

J Clin Psychiatry. 1996;57 Suppl 14:9-13. Review.

PMID:
9024331
8.

Early detection of Alzheimer's disease using neuroimaging.

Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ.

Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. Epub 2006 Jul 12. Review.

PMID:
16839732
9.

Imaging studies and APOE genotype in persons at risk for Alzheimer's disease.

Scarmeas N, Stern Y.

Curr Psychiatry Rep. 2006 Feb;8(1):11-7. Review.

10.

Investigations into geriatric psychiatry challenges: AAGP Senior Investigator Award 2000.

Small GW.

Am J Geriatr Psychiatry. 2000 Fall;8(4):276-83. Review.

PMID:
11069266
11.

Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.

Caselli RJ, Reiman EM.

J Alzheimers Dis. 2013;33 Suppl 1:S405-16. doi: 10.3233/JAD-2012-129026. Review.

12.

Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.

Villemagne VL, Rowe CC.

J Alzheimers Dis. 2013;33 Suppl 1:S349-59. Review.

PMID:
22710919
13.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease.

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20. Review.

14.

Neuroimaging in Alzheimer's disease: relevance for treatment.

van Dyck CH.

Curr Psychiatry Rep. 2001 Feb;3(1):13-9. Review.

PMID:
11177754
15.

Neuropathological changes in aging brain.

Xekardaki A, Kövari E, Gold G, Papadimitropoulou A, Giacobini E, Herrmann F, Giannakopoulos P, Bouras C.

Adv Exp Med Biol. 2015;821:11-7. doi: 10.1007/978-3-319-08939-3_6. Review.

PMID:
25416106
16.

Reduced neuronal activity and reactivation in Alzheimer's disease.

Swaab DF, Lucassen PJ, Salehi A, Scherder EJ, van Someren EJ, Verwer RW.

Prog Brain Res. 1998;117:343-77. Review.

PMID:
9932420
17.

Neuropathological alterations in Alzheimer disease.

Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189. doi: 10.1101/cshperspect.a006189. Review.

18.

Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun.

19.

Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.

Vanitallie TB.

Metabolism. 2013 Jan;62 Suppl 1:S30-3. doi: 10.1016/j.metabol.2012.08.024. Epub 2012 Sep 26. Review.

PMID:
23021038
20.

ApoE genotype accounts for the vast majority of AD risk and AD pathology.

Raber J, Huang Y, Ashford JW.

Neurobiol Aging. 2004 May-Jun;25(5):641-50. Review.

PMID:
15172743

Supplemental Content

Support Center